Commentary

Hepatitis A and E: not to be forgotten
Rana J. Asghar¹

The World Health Organization (WHO) estimates that every year hepatitis A virus (HAV) infection causes nearly 1.4 million new cases worldwide and the hepatitis E virus (HEV) is responsible for 20 million new infections and over 3 million acute cases. Although in most cases HAV and HEV infections are self-limiting, HAV is estimated to kill 100 000 people each year [1] and HEV nearly 60 000 people annually [2]. Pregnant women are at risk of more severe disease, obstetric complications and increased mortality if infected in the third trimester of pregnancy. The faecal–oral route is a well-established mode of transmission for both HAV and HEV and in the case of HEV infection person-to-person transmission is also an important factor in sporadic cases [3]. Outbreaks of HAV and HEV are therefore manifestations of the poor sanitation practices and lack of clean water supplies often found in developing countries. Humanitarian crises with large refugee populations can also be fertile ground for hepatitis outbreaks alongside cholera or other waterborne outbreaks, as was recently seen among Syrian refugees in Iraq [4]. Understanding the importance of the risk of hepatitis outbreaks in displaced populations can help in identifying outbreaks quickly and responding to them in a timely manner to reduce mortality and morbidity.

HAV has 7 genotypes, with little variation in their clinical expression. HEV has 4 genotypes with quite different clinical expressions, responsible for different disease manifestations across developing and developed countries. In developing countries genotype 1 is largely responsible for outbreaks and sporadic cases, via contamination of water and the fecal–oral route. Exceptions include Mexico in South America and countries in Africa, where genotype 2 is more common [5]. Neither HAV nor HEV have chronic states, although HEV is reported in immunocompromised people [6].

Acute HAV infection is often clinically indistinguishable from other causes of acute viral hepatitis, and laboratory confirmation is necessary. Diagnosis of HEV has its own challenges, which may result in an underestimation of the disease burden [6]. HAV has a very effective vaccine available, and the first vaccine for HEV was approved in China in December 2011, although it is not yet used in any other countries. Whereas HAV seroprevalence increases with age and comes close to 100% in highly endemic countries by the age of 5 years, HEV seroprevalence tends to stay between 5%–60% [7].

In 2010, the WHO World Health Assembly adopted resolution WHA63.18, which called for the prevention and control of viral hepatitis, with a focus on HBV and HCV [8]. This resolution came after Member States and WHO understood the gravity of the disease burden [6]. HAV has a very effective vaccine available, and the first vaccine for HEV was approved in China in December 2011, although it is not yet used in any other countries. Whereas HAV seroprevalence increases with age and comes close to 100% in highly endemic countries by the age of 5 years, HEV seroprevalence tends to stay between 5%–60% [7].

In 2010, the WHO World Health Assembly adopted resolution WHA63.18, which called for the prevention and control of viral hepatitis, with a focus on HBV and HCV [8]. This resolution came after Member States and WHO understood the gravity of the disease burden [6]. HAV has a very effective vaccine available, and the first vaccine for HEV was approved in China in December 2011, although it is not yet used in any other countries. Whereas HAV seroprevalence increases with age and comes close to 100% in highly endemic countries by the age of 5 years, HEV seroprevalence tends to stay between 5%–60% [7].

In 2010, the WHO World Health Assembly adopted resolution WHA63.18, which called for the prevention and control of viral hepatitis, with a focus on HBV and HCV [8]. This resolution came after Member States and WHO understood the gravity of the disease burden [6]. HAV has a very effective vaccine available, and the first vaccine for HEV was approved in China in December 2011, although it is not yet used in any other countries. Whereas HAV seroprevalence increases with age and comes close to 100% in highly endemic countries by the age of 5 years, HEV seroprevalence tends to stay between 5%–60% [7].

In 2010, the WHO World Health Assembly adopted resolution WHA63.18, which called for the prevention and control of viral hepatitis, with a focus on HBV and HCV [8]. This resolution came after Member States and WHO understood the gravity of the disease burden [6]. HAV has a very effective vaccine available, and the first vaccine for HEV was approved in China in December 2011, although it is not yet used in any other countries. Whereas HAV seroprevalence increases with age and comes close to 100% in highly endemic countries by the age of 5 years, HEV seroprevalence tends to stay between 5%–60% [7].

One major reason for this knowledge gap is that we are not looking for the evidence. In most developing countries, including most of those of the EMR, HEV is not routinely considered when a physician asks for investigations into a suspected case of viral hepatitis. Added to the diagnostic challenges is the fact that a majority of hepatitis-infected persons do not develop an acute condition that requires major health care intervention. HAV is in the same class, with few symptomatic cases reaching health-care settings, and as it is self-limiting in most cases, it is neither investigated nor reported to surveillance systems as HAV. Physicians also do not consider HAV or HEV to be serious illnesses, even though fulminant hepatitis, hepatic failure and death can occur from both infections.

More than 40% of the population of the EMR lives in just 2 countries, Egypt and Pakistan, both of which are considered endemic for HBC and HCV [8]. In Pakistan, the Field Epidemiology Laboratory Training Programme is collecting information about acute viral hepatitis cases via 5 sentinel sites throughout the country [13]. According to reports from the Pakistan viral hepatitis surveillance system HAV—responsible for more

¹South Asian Public Health Forum (jawad@alumni.washington.edu).
than 19% of all new infections—ranks second to HCV, while HEV—causing 12% of all newly diagnosed/acute cases of viral hepatitis—ranks third [14]. In Egypt, the importance of HAV has also been demonstrated through the local viral hepatitis sentinel system [15].

The lack of reliable data from the Region is preventing knowledge of the full extent of the burden of HAV and HEV in countries of the EMR. This in turn limits the ability of health planners to demonstrate to decision-makers the extent of the actual disease burden. The outcome is that fewer resources are prioritized for hepatitis control in EMR. Although our Region has all the precursors for the spread of these 2 types of hepatitis, we seem unable to better prepare ourselves to protect our populations. Awareness of HAV and HEV as major health challenges will be the first step towards effective hepatitis control strategies. Improved sanitation, provision of clean water and instigating vaccination where required could be the simple way to control both diseases. But sometimes simple is not easily accessible.

References